

April 1, 2026

**To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001**

**To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051**

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir/Madam,

Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Regulatory action/ inspection

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby submit the disclosure regarding the order passed by the Joint Commissioner of Central Goods & Service Tax and Central Excise, Mumbai East Commissionerate, passed under relevant provisions of the Central Goods and Services Tax Act, 2017 for the period FY 2019-20 and 2020-21 demanding GST amount along with interest and penalty.

The relevant details as required pursuant to Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are provided in “**Annexure A**”, enclosed herewith.

You are requested to take the above information on your records.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

**Harish Kuber
Company Secretary & Compliance Officer**

Encl: As above

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Annexure-A

Disclosure under Para A of Schedule III to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No.	Particulars	Information
1	Name of the Authority	Joint Commissioner of Central Goods & Service Tax and Central Excise, Mumbai East Commissionerate.
2	Nature and details of the action(s) taken, initiated or order(s) passed	Adjudication Order passed under section 74 and 122 of the Central Goods and Services Tax Act, 2017.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Order passed on 26.03.2026 received through email on 31.03.2026.
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	The order alleged to treat the transaction of sale of brand in FY 2020-21 as mixed supply and hence liable for higher rate of GST. Following demand have been raised in the order : <ol style="list-style-type: none"> 1. Rs.16,05,41,509/- on account of CGST/SGST alleged to be short paid by Glenmark. 2. Applicable interest on the above amount; 3. Rs.16,05,41,509/- towards penalty equivalent to the above tax amounts.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.	Based on the relevant facts of the case the Company is not accepting this demand and will be filing appeal before the appropriate authority. There is no material impact on the Company's financials, operations or other activities, due to said Order.

Glenmark Pharmaceuticals Limited

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com